Surgical Technology

Features of device for clearing arterial leg blockages extended to product line

Published in Heart Disease Weekly, October 23rd, 2005

Spectranetics Corporation (SPNC) announced it will extend features of the recently launched 2.5 Turbo product to its entire CLiRpath product line used for clearing arterial blockages in the leg.

Spectranetics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the "continuous on" lasing train to be added to its entire CliRpath product line.

Spectranetics plans to launch the expanded CliRpath Turbo product line after allowing for required software upgrades to be completed.

Many patients suffering from peripheral vascular disease and critical limb ischemia have total occlusions that cannot be crossed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Source: Heart Disease Weekly (2005-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry